Recce Pharmaceuticals Ltd (ASX:RCE)

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Research and Development of Pharmaceutical Drugs	9.47M	7.51M	5.03M	4.37M	3.08M
Total	9.47M	7.51M	5.03M	4.37M	3.08M

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Australia	7.36M	5.29M	3.83M	4.34M	2.84M
USA	1.97M	1.65M	1.37M	58.47K	317.16K
UK	43.45K	26.84K	26.81K	32.07K	23.01K
Unallocated	561.33K	733.30K	-	-	-
Total	9.94M	7.70M	5.24M	4.43M	3.18M

Data Source: S&P Global Market Intelligence Last updated: Aug 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 22, 2026

Data Sources Report a data error